PAPP-A as a Potential Target in Thyroid Eye Disease
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae339 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Cheryl A Conover und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Fibroblasts, Receptor, IGF Type 1, Pregnancy-Associated Plasma Protein-A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Context
Proptosis in thyroid eye disease (TED) can result in facial disfigurement and visual dysfunction. Treatment with insulin-like growth factor I receptor (IGF-IR) inhibitors has been shown to be effective in reducing proptosis but with side effects.
Objective
To test the hypothesis that inhibition of IGF-IR indirectly and more selectively with PAPP-A inhibitors attenuates IGF-IR signaling in TED. Informed consent was obtained from patients with TED undergoing surgery, and retro-orbital tissue was collected for fibroblast isolation and culture. Operations were performed in Mayo Clinic operating suites. Cell culture was performed in a sterile tissue culture facility. Retro-orbital tissue was collected from 19 patients with TED.
Methods
Treatment of TED fibroblasts with proinflammatory cytokines. Flow separation of CD34− and CD34+ orbital fibroblasts, the latter representing infiltrating fibrocytes into the orbit in TED. PAPP-A expression and proteolytic activity, IGF-I stimulation of phosphatidylinositol 3 kinase/Akt pathway, and inhibition by immuno-neutralizing antibodies against PAPP-A, CD34+ status, and associated PAPP-A and IGF-IR expression were measured.
Results
Proinflammatory cytokines markedly increased PAPP-A expression in TED fibroblasts. IGF-IR expression was not affected by cytokine treatment. Inhibition of PAPP-A's proteolytic activity suppressed IGF-IR activation in orbital fibroblasts from patients with TED. TED fibroblasts that were CD34+ represented ∼80% of the cells in culture and accounted for ∼70% of PAPP-A and IGF-IR–expressing cells.
Conclusion
These results support a role for PAPP-A in TED pathogenesis and indicate the potential for novel therapeutic targeting of the IGF axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Cheryl A Conover, Marius N Stan
Förderung
- NIAID NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Conover, C. A., Bale, L. K., & Stan, M. N. (2024). PAPP-A as a Potential Target in Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae339
Vancouver
Conover CA, Bale LK, Stan MN. PAPP-A as a Potential Target in Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae339
BibTeX
@article{Conover2024,
author = {Conover, Cheryl A and Bale, Laurie K and Stan, Marius N},
title = {PAPP-A as a Potential Target in Thyroid Eye Disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae339}
}
EUVIMED